ImmunityBio, Inc.: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Mar 12, 2018 and accepted by EDGAR at Mar 12, 2018, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-10-01 to 2017-12-31 | $12.0k | us-gaap:Revenues |
| Revenue | 12 months2017-01-01 to 2017-12-31 | $45.0k | us-gaap:Revenues |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $42.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2017-01-01 to 2017-12-31 | $57.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-10-01 to 2017-12-31 | −$25.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$99.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2017-01-01 to 2017-12-31 | $618.0k | us-gaap:InterestExpense |
| Income tax | 12 months2017-01-01 to 2017-12-31 | −$493.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-10-01 to 2017-12-31 | −$24.5m | us-gaap:NetIncomeLoss |
| Net income | 12 months2017-01-01 to 2017-12-31 | −$96.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-10-01 to 2017-12-31 | −$0.31 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | −$1.20 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $34.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2017-01-01 to 2017-12-31 | $15.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-12-31 | $23.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $132.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $250.4m | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $20.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $31.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $218.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-18-005290. Last ingested by Listed: Nov 9, 2026, 17:45 ET. Listed shows no prices and gives no investment advice.